Ketamine / KAPPending re-verificationDesignated-centers model

LCIP - Lausanne Centre for Interventional Psychiatry

Lausanne, Switzerland

Treatment & access

  • Treatments offeredIV ketamine infusions · Ketadex (ketamine + dexmedetomidine) · rTMS (repetitive transcranial magnetic stimulation) · Electroconvulsive therapy (ECT) · Anesthetic treatments for psychiatric indications (dexmedetomidine)
  • Access routeprivate_pay
  • Price informationLCIP states that IV ketamine infusions are not reimbursed by Swiss basic insurance or supplementary insurance and are paid by the patient; tariff details are available on request. Spravato can be covered for a maximum of 10 non-renewable months if prescription criteria are met, but LCIP states it is no longer offered to new patients at the centre.
  • Phone+41 21 320 10 05
  • Websitehttps://lcip.ch

About this provider

LCIP (Centre de psychiatrie interventionnelle de Lausanne) is an independent private outpatient centre founded in 2016, specialising in interventional psychiatry: IV ketamine infusions, rTMS, electroconvulsive therapy and anesthetic treatments for psychiatric indications including dexmedetomidine. Ketamine infusions are offered for severe unipolar or bipolar depressive episodes without psychotic symptoms, resistant anxiety disorders, OCD and PTSD, with a rapid antidepressant and anti-suicidal action. The initial protocol comprises ten infusions over ten weeks, followed by booster infusions on average every four weeks. Every infusion is individually dosed under continuous anesthetic monitoring, supervised by Dr Mall with an anesthesiology team, and a psychiatrist is permanently available. Patients are referred by their treating physician or psychiatrist.

Services & programs

  • IV ketamine infusionsPersonalised-dose infusions of about 45 minutes (total visit 1.5-2 hours) under continuous monitoring of blood pressure, oxygen saturation and ECG; initial course of 10 infusions over 10 weeks, then booster infusions on average every 4 weeks; fasting 6 hours for solids and 2 hours for liquids; no driving for 24 hours after treatment. Not reimbursed by basic or supplementary insurance per LCIP; self-pay, tariffs on request.
  • Ketadex (ketamine + dexmedetomidine)Combination described by LCIP as reinforcing and prolonging therapeutic benefits while attenuating dissociative effects, suited to patients who fear or do not tolerate dissociation from ketamine alone. Not published on the provider's website.
  • rTMSNon-invasive neurostimulation for resistant depression, OCD, anxiety disorders and chronic neuropathic pain. Not published on the provider's website.
  • Electroconvulsive therapy (ECT)Reference treatment for severe depression, bipolar disorder and resistant schizophrenia, which LCIP notes can be considered first-line in the most severe resistant depressions requiring an immediate response. Not published on the provider's website.

Programs & studies

ProgramKindStatus
IV ketamine infusion programme
LCIP explicitly does not offer ketamine-assisted psychotherapy; it follows pharmacological protocols with anesthetic monitoring and cites response rates of 50-70% and complete remission in 30% in resistant depression.
ketamine_ivoffered
Spravato (esketamine nasal spray)
LCIP states Spravato can be insurer-covered for a maximum of 10 non-renewable months for eligible patients, but is currently not proposed to new patients at the centre.
esketamine_nasalno longer offered to new patients
Ketadex (ketamine + dexmedetomidine)
Offered for patients who do not tolerate or fear dissociative effects of ketamine alone.
ketamine_combinationoffered

Pricing

ItemPrice
IV ketamine infusions
LCIP states infusions are not reimbursed by basic or supplementary insurance in Switzerland; treatments including psychiatry and anesthesia supervision are at the patient's charge, with tariff information available on request.
Not published

Prices are taken from the provider's own website and were last checked on . Always confirm the current price with the provider before booking.

Facilities & languages

  • Facilities
    • Comfortable dimmed-light infusion room with optional soft music
    • Continuous vital-sign monitoring (blood pressure, oxygen saturation, ECG)
  • LanguagesWebsite in French with a full English version; the centre is located in Lausanne (French-speaking Switzerland).
  • TeamTeam of psychiatrists and anesthetists; all ketamine infusions are supervised by Dr Mall in collaboration with the anesthesiology team, with an anesthesia nurse or anesthetist present throughout and a psychiatrist permanently available.

Common questions

Is IV ketamine covered by Swiss insurance at LCIP?

No. LCIP states that IV ketamine infusions are not reimbursed by basic insurance (OKP) or supplementary insurance in Switzerland; the treatment is self-pay, and tariff and payment details are provided on request. Spravato can be covered for up to 10 non-renewable months for eligible patients, but LCIP no longer offers it to new patients.

How are patients referred?

Patients are referred by their treating physician or psychiatrist, who sends a summary of the situation and continues follow-up in parallel. An initial in-person evaluation by a psychiatrist and an anesthetist then determines whether treatment can proceed.

Is treatment inpatient or outpatient?

All care is outpatient; LCIP is a private ambulatory centre with no hospitalisation, independent of public hospital structures.

What does a ketamine session look like?

After fasting (6 hours solids, 2 hours liquids), the patient receives a personalised-dose infusion of about 45 minutes in a quiet, dimly lit room under continuous monitoring, followed by observation; the whole visit lasts about 1.5-2 hours. Driving is prohibited for 24 hours and an accompanied trip home is required.

How many sessions are needed?

Typically 10 infusions over 10 weeks at decreasing frequency, then booster infusions on average every 4 weeks depending on response; if there is no response after 5 infusions, other treatments are proposed.

Looking at alternatives? Other Swiss options include BAG-designated centres providing esketamine (Spravato) with insurer coverage, providers authorised under the federal limited medical use programme for psychedelic-assisted therapy, and clinical trials at university psychiatric hospitals.

Verification

This record was verified previously and is awaiting its scheduled re-check against the registry.

  • License / registryPublic trial registry (ClinicalTrials.gov / EU CTIS)
  • Sourcehttps://lcip.ch
  • Last verified

Spotted an error? See our methodology for how records are checked and how to report a correction.